close
MENU
How to guide
How to guide
Home
The NBR List
NBR View
NBR Marketplace

Categories

General Business Investment Economics Te Ao Māori Politics Infrastructure Australia Tech & Innovation Finance Law Professional Services Primary Industries Retail Property Deals Aviation News Comings & Goings

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

Podcasts Audio Articles Entrepreneurs Your Business Beehive Banter Morning Brew Toil & Trouble NZ Aviation News Back Issues Market Outlook Dollars & Sense Private Bin Opinion (Archive) NBR Radar (Archive) NBR Rich List (Archive)
General Business
3 mins to read

AFT grows sales, refinances debt, eyes dividend next year

The dual-listed company saw sales increase during Covid pandemic, despite licensing deals delayed.

Julie Iles Thu, 19 Nov 2020

Dual-listed AFT Pharmaceuticals sales have grown despite Covid-19, though the pandemic has slowed some development work on licensing deals.

Group operating revenue for the six months to September 30 grew by 4% to $48.8 million, while in Australia, the largest market, revenue was boosted by 11%.

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Julie Iles Thu, 19 Nov 2020
Contact the Writer: julie@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
AFT Pharmaceuticals Hartley Atkinson David Flacks
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Related News
General Business

AFT creates Irish subsidiary to serve as European base
General Business

AFT share sell-down, capital raise add $73.8m in liquidity
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Related News
General Business

AFT creates Irish subsidiary to serve as European base
General Business

AFT share sell-down, capital raise add $73.8m in liquidity
AFT grows sales, refinances debt, eyes dividend next year
General Business,
85632
true
Subscribe Login